Chee K H, Choo G H, Jamaluddin A N B, Mahendran K, Greenlaw N, Chandran A
University of Malaya, Faculty of Medicine, Kuala Lumpur, Malaysia.
Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia.
Med J Malaysia. 2017 Oct;72(5):282-285.
The on-going, international, prospective, observational, longitudinal CLARIFY registry is investigating the demographics, clinical profiles, management and outcomes of patients with stable coronary artery disease (CAD). This paper assesses baseline characteristics, treatment, and clinical outcomes at two years' follow-up of Malaysian/Bruneian patients compared with the overall registry population.
Between November 2009 and July 2010, outpatients from 45 countries who met the criteria for stable CAD were recruited into the registry. Baseline characteristics were documented at enrolment, and patients were reassessed during their annual visits over a five-year follow-up period. Key outcomes measured were sudden death and cardiovascular (CV) death, non-CV death and CV morbidity.
At baseline, 33,283 patients were available for analysis within the registry; 380 and 27 were Malaysians and Bruneians, respectively. The mean ages of Malaysian/Bruneian patients and the rest of the world (RoW) were 57.83 ±9.98 years and 64.23 ± 10.46 years, respectively (p<0.001). The median body mass index values were 26.6 (24.4-29.6) kg/m and 27.3 (24.8-30.3) kg/m, respectively (p=0.014). Malaysian/Bruneian patients had lower rates of myocardial infarction (54.55% versus 59.76%, p=0.033) and higher rates of diabetes (43.24% versus 28.99%, p<0.001) and dyslipidaemia (90.42% versus 74.66%, p<0.001) compared with the RoW. Measured clinical outcomes in Malaysian and Bruneian patients at 2-years follow-up were low and generally comparable to the RoW.
Malaysian/Bruneian patients with stable CAD tend to be younger with poorer diabetic control compared with the RoW. However, they had similar outcomes as the main registry following two years of treatment.
正在进行的国际前瞻性观察性纵向CLARIFY注册研究，旨在调查稳定型冠状动脉疾病（CAD）患者的人口统计学、临床特征、治疗情况及预后。本文评估了马来西亚/文莱患者在两年随访期的基线特征、治疗及临床结局，并与整个注册研究人群进行比较。
2009年11月至2010年7月，来自45个国家符合稳定型CAD标准的门诊患者被纳入该注册研究。在入组时记录基线特征，并在为期五年的随访期内每年复诊时对患者进行重新评估。测量的主要结局为心源性猝死和心血管（CV）死亡、非CV死亡及CV发病情况。
在基线时，注册研究中有33283例患者可供分析；其中马来西亚人和文莱人分别为380例和27例。马来西亚/文莱患者与世界其他地区（RoW）患者的平均年龄分别为57.83±9.98岁和64.23±10.46岁（p<0.001）。体重指数中位数分别为26.6（24.4 - 29.6）kg/m²和27.3（(24.8 - 30.3）kg/m²（p = 0.014）。与RoW患者相比，马来西亚/文莱患者心肌梗死发生率较低（54.55%对59.76%，p = 0.033），而糖尿病（43.24%对28.99%，p<0.001）和血脂异常（90.42%对74.66%，p<0.001）发生率较高。在两年随访期，马来西亚和文莱患者的测量临床结局较低，且总体与RoW患者相当。
与RoW患者相比，患有稳定型CAD的马来西亚/文莱患者往往更年轻，但糖尿病控制较差。然而，经过两年治疗后，他们的结局与主要注册研究人群相似。
